VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has announced a technical milestone in the detection of nucleosomes from capillary blood samples obtained via a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, successfully demonstrated the feasibility of detecting nucleosomes in capillary samples from critically ill patients with sepsis. This development could significantly expand access to diagnostic testing in point-of-care and non-laboratory settings, particularly for early detection of immune disruptions associated with conditions such as sepsis.
According to the company, the prototype builds on prior results that showed a strong correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. The ability to use capillary blood, obtained through a simple finger prick, simplifies sample collection and reduces the need for venipuncture, which could be especially beneficial in resource-limited environments. Volition noted that this approach could broaden its addressable market and support future commercialization efforts, including potential partnerships aimed at increasing access in regions with limited laboratory infrastructure.
The implications of this breakthrough are significant for the management of sepsis, a life-threatening condition that requires rapid diagnosis and treatment. Early detection of nucleosomes, which are markers of cell death and NETosis, could enable earlier intervention and improve patient outcomes. The point-of-care format also has the potential to decentralize testing, bringing diagnostics closer to patients in emergency rooms, intensive care units, and even remote or underserved areas.
Volition’s research and development activities are centered in Belgium, with additional offices in the U.S. and London. The company is focused on advancing the science of epigenetics to develop simple, cost-effective blood tests for early detection and monitoring of diseases, including cancers and sepsis. The SUMMIT program, under which this study was conducted, is a key part of Volition’s efforts to validate its technology across multiple clinical applications.
For more details, the full press release is available at https://ibn.fm/ioEmu. Further information about the company and its technology can be found on its website at Volition.com.
